News
Is this Australia’s next biotech success story?
One of the most advanced cancer therapies on the ASX, Prescient Therapeutics’ (ASX: PTX) PTX-100 is currently in Phase 2a trials for its first targeted cancer, Cutaneous T-Cell Lymphoma (CTCL), which many clinicians see as a death sentence in the…
Aussie medtech readies ASX IPO to combat world’s second-biggest killer
MedTech has been a standout sector this year with capital flowing into technologies that can deliver proven, actionable insights with demonstrated impact on patients’ lives. One company that is riding this wave and is setting its sights on an ASX…
Aussie company solving military supply issues for the US, UK and Ukraine
Supply chain failure is one of the biggest operational barriers in an active warzone and can be the difference between life and death. SPEE3D is solving this with state-of-the-art, field-deployable metal printing technology, currently deployed with six defence forces globally….
How this ASX biotech could potentially address 22% of all cancers worldwide
One of the most advanced cancer therapies on the ASX, Prescient Therapeutics’ (ASX: PTX) PTX-100 is a first-in-class technology which has seen the cancer halt or reduce in 100% of assessable CTCL patients and zero drug related serious adverse events....
The critical mineral behind AI chips: Why existing suppliers can’t meet demands
Advanced Energy Minerals (ASX: AEM) is the only ASX-listed commercial-scale High Purity Alumina (HPA) producer and one of the only companies globally able to produce ultra-low alpha HPA at commercial scale - a critical material used in advanced AI chips. China controls...
Aussies in Silicon Valley Winning Business Off Databricks and Snowflake
Having moved to Silicon Valley, Australian big data / AI company Zetaris is at the centre of solving one of the biggest bottlenecks within the most significant shift in our lifetime, targeting a billion dollar plus exit in the next 1-2...
How individuals can unlock 13%+ yield private credit opportunities
If you’re an Australian investor asking, “Where can I still get a decent cash yield?” – you’re not alone.
The Australian AI company aiming for a $1 billion+ exit
Australian big data company Xsights has managed what most tech companies dream of: the potential to sign contracts worth $100s million ARR with companies worth $100s billion, driven mostly by inbound demand.
Why the FDA backs ASX-biotech to revolutionise cancer treatment
One in five people will get cancer in their lifetime – almost everyone has been touched by the disease in one way or another.
The Aussie mining veterans looking to build the largest exploration company on the planet
A potential once-in-a-generation opportunity has opened up for the companies that can deliver the critical metals projects the world needs for the green energy transition.
Felix Gold: The Leading U.S. Antimony Solution at a Critical Moment
The global antimony market has undergone a dramatic transformation.
Aussie big data company disrupts the ~$300bn pork industry
Australian tech company Xsights is set to disrupt the ~$300 billion global pork production market.
Connecting quality investors and innovative companies to facilitate mutual wealth creation with trust and transparency
By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement.